PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials

被引：0
|
作者：
Papp, Kim [1 ,2 ]
Vender, Ronald [3 ]
Langley, Richard [4 ]
Ho, Vincent [5 ]
Park-Wyllie, Laura [6 ]
Abbarin, Nastaran [6 ]
Miller, Megan [7 ]
You, Yin [7 ]
Yang, Ya-Wen [8 ]
机构：
[1] Probity Med Res Inc, Waterloo, ON, Canada
[2] K Papp Clin Res, Waterloo, ON, Canada
[3] McMaster Univ, Div Dermatol, Dept Med, Hamilton, ON, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[6] Janssen Inc, Janssen Med Affairs, Toronto, ON, Canada
[7] Janssen Res & Dev LLC, Spring House, PA USA
[8] Janssen Pharmaceut Companies Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB203 / AB203
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2
    Kimball, A. B.
    Foley, P.
    Thaci, D.
    Vender, R.
    Song, M.
    Li, S.
    Fakharzadeh, S.
    Shen, Y. -K.
    Armstrong, A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB233 - AB233
  • [32] Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
    Reich, Kristian
    Dutz, Jan
    Foley, Peter
    Thaci, Diamant
    Vender, Ron
    Song, Michael
    Miller, Megan
    Yu, Yin
    Li, Shu
    Shen, Yaung-Kaung
    Armstrong, April W.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [33] Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial
    Sonkoly, Enikoe
    Maul, Julia-Tatjana
    Megna, Matteo
    Gorecki, Patricia
    Crombag, Edmee
    Buyze, Jozefien
    Savage, Laura
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [34] Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials
    Blauvelt, A.
    Reich, K.
    Spelman, L.
    Bagel, J.
    Bissonnette, R.
    Gerdes, S.
    Fakharzadeh, S.
    Song, M.
    Shen, Y. -K.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 52 - 53
  • [35] Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials
    Blauvelt, A.
    Reich, K.
    Spelman, L.
    Bagel, J.
    Bissonnette, R.
    Gerdes, S.
    Fakharzadeh, S.
    Song, M.
    Shen, Y-K
    Gordon, K. B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB38 - AB38
  • [36] MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL
    Griffiths, C. E. M.
    Papp, K.
    Song, M.
    Miller, M.
    You, Y.
    Shen, Y. K.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1297 - 1298
  • [37] Long-term safety of guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment
    Blauvelt, A.
    Gordon, K.
    Griffiths, C.
    Papp, K.
    Foley, P.
    Song, M.
    Miller, M.
    Shen, Y. -K.
    You, Y.
    Ramachandran, P.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E52 - E52
  • [38] Maintenance of response with guselkumab for up to 3 years' treatment in the phase 3 VOYAGE 1 trial of patients with plaque psoriasis
    Griffiths, C. E.
    Papp, K. A.
    Song, M.
    Randazzo, B.
    Li, S.
    Shen, Y. -K.
    Han, C.
    Blauvelt, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 49 - 50
  • [39] SPEED OF RESPONSE OF GUSELKUMAB COMPARED WITH ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-BLINDED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS
    Blauvelt, Andrew
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 21 - 21
  • [40] Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
    Merola, Joseph F.
    Thaci, Diamant
    Choi, Olivia
    Chan, Daphne
    Yang, Ya-Wen
    Miller, Megan
    You, Yin
    Li, Shu
    Blauvelt, Andrew
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB170 - AB170
12345